5.B - top down and bottom up strategies Flashcards
key idea
- whether its better/easier/more effective to use top down or bottom up strategies for disease eradication
what are top down strategies?
- government led campaigns to eradicate diseases using a combination of direct/indirect strategies often with people being told what to do
what are bottom up strategies?
- where communities make their own strategies and they are consulted
- often this is with NGOs and relies more on indirect strategies such as sdeducation to tackle disease
what role do TNCs play in disease eradication?
- e.g. GlaxoSmithKlein
- for diseases to be eradicated on whatever scale, you need a TNC with the wealth, expertise and resources to generate the drugs, the technology to administer the drugs and the ability to modify these if/when the disease mutates
- political will is also needed, as is money to pay. often comes from national govts/international agencies eg. WHO or large aid investors e.g. Bill and Melinda Gates
why are top down sometimes unsuccessful?
- social/cultural reasons
- e.g. difficult to eradicate Polio in Pakistan as the Taliban, who control large areas of Pakistan, have not allowed the vaccines to be administered
- there have been enormous movements of people which have meant that it has been hard to keep track of who has/has not been vaccinated
- there was a distinct mistrust of the ‘outsiders’ coming in to vaccinate children
where do bottom up strategies come into play?
- it is essential that the country/people in the country ‘buy in’ to the eradication strategy and this is where the conceptual approach of bottom up strategies come into play
- where local people and communities are trained/educated and then worked with collaboratively to tackle a disease
- often working with women in these communities is most important as in LIDCs women will do most of the household chores/raise the children.
who are GSK
- GlaxoSmithKline
- Market capitalisation of £81 billion
- drugs and vaccines earned £21.3 billion in 2013
why do GSK have a bad reputation in Africa?
- bad reputation in Africa for high cost of HIV drugs in the past
- they sold their drug 5000x more expensive than it is. reinvented an existing drug for a limited market.
- to reform, they have controversially partnered with Save the Children, aiming not to generate profit or loss by donating £15 bill in 2013
what do GSK want?
- to tackle the root cause of disease
- help transform millions of lives
- working to get new treatments to everyone who needs it
- price their products at levels each country is able to pay
- they’ve reached 300,000 patients, 64 countries and 300 clinical trials so far
GSK criminal trial
- pleased guilty to the promotion of drugs for unapproved uses and failure to report safety data
- “Advair” = asthma drug sold for uses that weren’t approved by FDA
- paid £1.9bn settlement
- largest healthcare fraud to date
when have GSK faced criticism?
- in 2009 they said they would cut drug prices by 25% for 50 poorest nations
- criticised for not helping NEEs and excluding HIV from this
how many countries do GSK work in?
operations are global with 84 manufacturing sites in 36 different countries
what is their main turnover?
2/3 of their turnover is from pharmaceuticals, including medicines for a range of acute and chronic diseases
how may vaccines where distributed in 2014 and where did most go?
- over 800 million doses of vaccines
- of which 80% went to countries in the developing world
give 3 well known drugs that it distributes
- Amoxicillin to fight bacterial infections
- Zidovudine for HIV infection
- bendazole to combat parasitic infections
- the drugs are on WHO’s list of essential medicines
outline GSK’s investment in research and development
- employs 13,000 people in R&D and spends more than £3 billion researching new medecines
- usually taken in partnership w/ other companies, unis and research charities
how is GSK helping LIDCs?
- one of the few companies currently researching treatments for WHO’s 3 priority diseases (HIV/AIDs, malaria and TB)
- problem it faces is that demand for new drugs in LIDCs, whose economies are weak, is often too small to recoup development costs
- despite the problems, GSK devotes significant R&D resources to the needs of the developing world
- e.g its research centre in Spain focuses primarily on TB, malaria and other tropical diseases
- the company is close to launching the first effective vaccine against malaria
- its also developing a vaccine for the ebola virus.
give 5 GSK ethical policies
- a commitment to a small return (5%) on each product sold
- providing 3 HIV/AIDs drugs to LIDCs at significant discount
- granting licences for the manufacture of cheap generic versions of its patented drugs
- capping the price of patented drugs for developing countries to 25% of the UK price
- investing 20% of its profits from sales in each developing country into that country’s health infrastructure
how sig are TNCs in reducing disease risk?
- money - a lot more than govts/NGOs
- most sig in developing countries
should TNCs be this significant?
- unsettling that they determine price and therefore a country’s ability to protect its citizens
what are top-down global strategies?
- include strategies such as vaccination campaigns, research and development of effective treatments and pharmaceutical drugs
- institutions such as the WHO coordinating health initiatives, surveillance and monitoring on a global scale such as flows of people, implementing awareness/education schemes on a global scale
- and providing financial aid to everyone in need
example of top down global strategy?
- small pox eradication
- they used global topdown strategies such as universal childhood immunisation programmes, mass vaccination in other groups of people, surveillance and commitment strategies to track the spread
- this meant that by 1980 small pox was fully eradicated
why was the small pox eradication successful? (top down global strategy)
- successfully eradicated smallpox across the globe
- this was so successful because it ensured that recurrent infectivity did not occur
- they did this by making sure that there was no animal reservoir that carried small pox, and that there was an effective stable vaccine available
- because this was done on a global scale it ensured that everywhere had the resources/infrastructure to be able to eradicate smallpox.
what are the limitations of top down global strategies?
- often require significant financial resources, manpower and infrastructure to implement effectively
- this can strain the resources of both donor countries and international organisations
- the global campaign to eradicate smallpox, led by the WHO, cost around $400 mill USD
- without ongoing efforts there is a risk of resurgence, especially if surveillance systems are weakened or vaccine coverage declines. this requires long term commitment and investment
- top down strategies may not always address the underlying issues of equity and access to healthcare services
- marginalised communities or regions with limited resources may be left behind, perpetuating health inequalities